公开(公告)号：WO2012112396A3

公开(公告)日：2012-10-26

申请号：PCT/US2012024691

申请日：2012-02-10

Applicant: ELLIPSE TECHNOLOGIES INC ,  POOL SCOTT ,  GREEN STUART A ,  ROSCHAK EDMUND J

Inventor： POOL SCOTT ,  GREEN STUART A ,  ROSCHAK EDMUND J

IPC: A61B17/82 ,  A61B17/66 ,  A61B17/86 ,  A61F2/28

CPC classification number: A61B17/7216 ,  A61B17/1725 ,  A61B17/68 ,  A61B17/921 ,  A61B50/30 ,  A61B50/33 ,  A61B50/34 ,  A61B2017/00411 ,  A61B2017/00845 ,  A61B2017/681 ,  A61F2/28

Abstract: A variable length nail is provided with at least 5 mm of axial length change in each direction. An external adjustment device having at least one rotatable magnet is placed in proximity to the patient's skin. The external adjustment device is operated so that a magnetic field of the at least one rotatable magnet of the external adjustment device causes the rotatable permanent magnet of the variable length nail to rotate, causing either extension or retraction of the distraction shaft relative to the housing. In another embodiment, a rotational correction system is provided in which the bone implant has first and second sections that rotate with respect to one another in response to a magnetic field applied by the external adjustment device. In this regard, rotational adjustment of two bone sections may be accomplished.

Abstract translation: 可变长度的钉子在每个方向上具有至少5mm的轴向长度变化。 具有至少一个可旋转磁体的外部调节装置被放置在患者皮肤附近。 操作外部调节装置，使得外部调节装置的至少一个可旋转磁体的磁场使可变长度钉的可旋转永磁体旋转，从而引起分离轴相对于壳体的伸出或缩回。 在另一个实施例中，提供一种旋转校正系统，其中骨植入物具有响应于外部调节装置施加的磁场而相对于彼此旋转的第一部分和第二部分。 在这方面，可以实现两个骨段的旋转调整。

公开(公告)号：WO2012112396A2

公开(公告)日：2012-08-23

申请号：PCT/US2012/024691

申请日：2012-02-10

Applicant: ELLIPSE TECHNOLOGIES, INC. ,  POOL, Scott ,  GREEN, Stuart, A. ,  ROSCHAK, Edmund, J.

Inventor： POOL, Scott ,  GREEN, Stuart, A. ,  ROSCHAK, Edmund, J.

IPC: A61B17/82 ,  A61B17/66 ,  A61B17/86 ,  A61F2/28

CPC classification number: A61B17/7216 ,  A61B17/1725 ,  A61B17/68 ,  A61B17/921 ,  A61B50/30 ,  A61B50/33 ,  A61B50/34 ,  A61B2017/00411 ,  A61B2017/00845 ,  A61B2017/681 ,  A61F2/28

Abstract: A variable length nail is provided with at least 5 mm of axial length change in each direction. An external adjustment device having at least one rotatable magnet is placed in proximity to the patient's skin. The external adjustment device is operated so that a magnetic field of the at least one rotatable magnet of the external adjustment device causes the rotatable permanent magnet of the variable length nail to rotate, causing either extension or retraction of the distraction shaft relative to the housing. In another embodiment, a rotational correction system is provided in which the bone implant has first and second sections that rotate with respect to one another in response to a magnetic field applied by the external adjustment device. In this regard, rotational adjustment of two bone sections may be accomplished.

Abstract translation: 可变长度的钉在每个方向上具有至少5mm的轴向长度变化。 具有至少一个可旋转磁体的外部调节装置放置在患者皮肤附近。 操作外部调节装置，使得外部调节装置的至少一个可旋转磁体的磁场使得可变长度的钉的可旋转永磁体旋转，从而引起牵引轴相对于壳体的延伸或缩回。 在另一个实施例中，提供了一种旋转校正系统，其中骨植入物具有响应于由外部调节装置施加的磁场相对于彼此旋转的第一和第二部分。 在这方面，可以实现两个骨段的旋转调节。

公开(公告)号：WO2007044296A2

公开(公告)日：2007-04-19

申请号：PCT/US2006038419

申请日：2006-09-29

Applicant: MERCK & CO INC ,  GOTTESDIENER KEITH M ,  GREEN STUART A ,  MACINTYRE EUAN

Inventor： GOTTESDIENER KEITH M ,  GREEN STUART A ,  MACINTYRE EUAN

CPC classification number: A61K31/4015 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/454 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.

Abstract translation: 本发明涉及用于治疗尿频，尿急和尿失禁的组合物，其包含（R）-N- [4- [2 - [[2-羟基-2-（吡啶-3-基）乙基]氨基]乙基] 苯基] -4- [4-（4-三氟甲基苯基）噻唑-2-基]苯磺酰胺及其药学上可接受的盐。 另一方面，本发明涉及用于尿频，尿急和尿失禁的组合疗法，其中活性剂之一是（R）-N- [4- [2 - [[2-羟基-2-（吡啶-3-基） 乙基]氨基]乙基]苯基] -4- [4-（4-三氟甲基苯基）噻唑-2-基]苯磺酰胺及其药学上可接受的盐。

公开(公告)号：WO2008121268A1

公开(公告)日：2008-10-09

申请号：PCT/US2008/003873

申请日：2008-03-25

Applicant: MERCK & CO., INC. ,  FRENKL, Tara ,  GREEN, Stuart, A. ,  MACINTYRE, Euan ,  MILLS, Sander, G.

Inventor： FRENKL, Tara ,  GREEN, Stuart, A. ,  MACINTYRE, Euan ,  MILLS, Sander, G.

IPC: A01N43/42 ,  A61K31/47

CPC classification number: A61K31/47 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention concerns compositions for the treatment of Lower Urinary Tract Symptoms (LUTS), and especially LUTS which results from benign prostatic hypertrophy. The compositions of the invention comprise a Beta-3 agonist described below, optionally in combination with a 5-alpha reductase inhibitor, or an NK-1 antagonist or an alpha-1 adrenergic antagonist or an anti-muscarinic agent. The invention also includes compositions comprising a beta-3 agonist and two additional active agents selected from a 5-alpha reductase inhibitor, an NK-1 antagonist, an alpha-1 adrenergic antagonist or an anti-muscarinic agent.

Abstract translation: 本发明涉及用于治疗下尿路症状（LUTS）的组合物，特别是由良性前列腺肥大引起的LUTS。 本发明的组合物包含下述的β-3激动剂，任选地与5-α还原酶抑制剂或NK-1拮抗剂或α-1肾上腺素能拮抗剂或抗毒蕈碱剂组合。 本发明还包括包含β-3激动剂和选自5-α还原酶抑制剂，NK-1拮抗剂，α-1肾上腺素能拮抗剂或抗毒蕈碱剂的另外的活性剂的组合物。

公开(公告)号：WO2007146224A2

公开(公告)日：2007-12-21

申请号：PCT/US2007/013683

申请日：2007-06-07

Applicant: MERCK & CO., INC. ,  GOTTESDIENER, Keith, M. ,  GREEN, Stuart, A. ,  MACINTYRE, Euan

Inventor： GOTTESDIENER, Keith, M. ,  GREEN, Stuart, A. ,  MACINTYRE, Euan

IPC: A61K31/4015

CPC classification number: A61K31/4015 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pharmaceutically acceptable salt thereof. This invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and another is an anti-muscarinic agent or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及用于治疗尿频，尿急和尿失禁的组合物，其包含选择的NK-1受体拮抗剂或其药学上可接受的盐和抗毒蕈碱剂或其药学上可接受的盐。 本发明涉及尿频，尿急和尿失禁的联合治疗，其中一种活性剂是选择的NK-1受体拮抗剂或其药学上可接受的盐，另一种是抗毒蕈碱剂或其药学上可接受的盐 。

公开(公告)号：WO2007146224A3

公开(公告)日：2008-02-14

申请号：PCT/US2007013683

申请日：2007-06-07

Applicant: MERCK & CO INC ,  GOTTESDIENER KEITH M ,  GREEN STUART A ,  MACINTYRE EUAN

Inventor： GOTTESDIENER KEITH M ,  GREEN STUART A ,  MACINTYRE EUAN

IPC: A01N33/02 ,  A61K31/135

CPC classification number: A61K31/4015 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pharmaceutically acceptable salt thereof. This invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and another is an anti-muscarinic agent or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及用于治疗尿频，尿急和尿失禁的组合物，其包含选择的NK-1受体拮抗剂或其药学上可接受的盐和抗毒蕈碱剂或其药学上可接受的盐。 本发明涉及尿频，尿急和尿失禁的联合治疗，其中一种活性剂是选择的NK-1受体拮抗剂或其药学上可接受的盐，另一种是抗毒蕈碱剂或其药学上可接受的盐 。

公开(公告)号：WO2007044296A3

公开(公告)日：2007-04-19

申请号：PCT/US2006/038419

申请日：2006-09-29

Applicant: MERCK & CO., INC. ,  GOTTESDIENER, Keith, M. ,  GREEN, Stuart, A. ,  MACINTYRE, Euan

Inventor： GOTTESDIENER, Keith, M. ,  GREEN, Stuart, A. ,  MACINTYRE, Euan

IPC: A61K31/4439 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/454

Abstract: This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising ( R )- N -[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is ( R )- N -[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.